Norsat is very undervalued, says Global Maxfin’s Garcea

Norsat CEO Dr. Amiee Chan. Global Maxfin analyst Ralph Garcea says Norsat’s management team has demonstrated experience at deriving value from acquisitions.

Yesterday, Norsat (Norsat Stock Quote, Chart, News: TSX:NII) acquired the assets of an unnamed US-based satellite communication systems company for (US) $530,170.

The Richmond, BC, based company said the pickup would allow it to additional areas within the satellite communications markets with solid state power amplifiers, high power block upconverters, SATCOM baseband kits and Microsatellite terminals.

Norsat CEO, Dr. Amiee Chan, said the new types of business afforded by the acquisition can make a meaningful contribution.

“Strategically, this acquisition is consistent with Norsat’s ongoing growth strategy. Through it, we will broaden our portfolio of products and services, and the solutions we provide to customers,” she said. “The expanded sales team and larger product range it brings will enable us to address new market opportunities in the US and around the world. Accordingly, we believe the acquisition will create strong value and has the potential to be accretive to shareholders.”

Global Maxfin Capital analyst Ralph Garcea says this addition is a great strategic fit for Norsat in terms of product and intellectual property. He thinks the deal could add more than $5-million in revenue and half a million dollars in EBITDA annually. He says Norsat’s management team has demonstrated experience at deriving value from acquisitions, pointing to the 2011 acquisition of Sinclair. In a research update to clients yesterday, Garcea reiterated his STRONG BUY rating and $1.00 target on Norsat.

Garcea says Norsat is undervalued relative to its peers. He says the company is currently trading at an EV/Sales of 0.7x and EV/EBITDA of 6.0x, but its comparables are trading at 1.1x and 7.5x, respectively. Recent takeout multiples in the space, he points out, are even higher, at 1-2.5x EV/Sales and 8-12x EV/EBITDA. These numbers, says the Global Maxfin analyst, support a C$1.25-1.50 takeout value for Norsat.

At press time, shares of Norsat were up 2% to $.51.

Tagged with: nii
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

View Comments

  • "Global Maxfin Capital analyst Ralph Garcea says this addition is a great strategic fit for Norsat in terms of product and intellectual property. He thinks the deal could add more than $5-million in revenue and half a million dollars in EBITDA annually. "

    Typical analyst BS. How can he determine revenue and EBITDA without knowing anything about the company that was bought.

Recent Posts

Tilray: why this analyst just cut his price target

Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]

21 hours ago

Why National Bank likes Anaergia right now

National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]

21 hours ago

Canada’s provinces are leading investment boom, RBC says

RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]

21 hours ago

Can Eupraxia Pharmaceuticals stock go even higher?

Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]

21 hours ago

Is it time to buy VersaBank stock?

Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]

21 hours ago

Rapid Micro Biosystems has a 240% upside, this analyst says

Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]

21 hours ago